tiprankstipranks
Trending News
More News >
Tsumura & Co. (JP:4540)
:4540

Tsumura & Co (4540) AI Stock Analysis

Compare
1 Followers

Top Page

JP

Tsumura & Co

(OTC:4540)

Rating:69Neutral
Price Target:
¥3,756.00
▲(7.22%Upside)
The overall score of 68.8 reflects strong financial performance and attractive valuation metrics, offset by bearish technical indicators. The stock's low P/E ratio and solid dividend yield are major positives, but current price momentum is a significant risk factor.

Tsumura & Co (4540) vs. iShares MSCI Japan ETF (EWJ)

Tsumura & Co Business Overview & Revenue Model

Company DescriptionTsumura & Co. engages in the manufacture and sale of pharmaceutical products worldwide. The company offers Kampo extract intermediates and granular Kampo formulations. It is involved in the procurement, selection and processing, and storage of raw material crude drugs and crude drug pieces for decoction; manufacture of Kampo powdered extracts and traditional Chinese medicines; and sale of pharmaceuticals and food products. The company was founded in 1893 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyTsumura & Co primarily generates revenue through the sale of its Kampo medicines. The company develops, manufactures, and distributes these herbal products to healthcare professionals, pharmacies, and hospitals. This revenue stream is supported by Tsumura's robust research and development efforts, which ensure the efficacy and safety of their products. Additionally, the company may engage in partnerships with other pharmaceutical companies and research institutions to enhance their product offerings and expand their market reach. Tsumura's focus on quality control and adhering to stringent regulatory standards further solidifies its position in the market, contributing to its revenue generation.

Tsumura & Co Financial Statement Overview

Summary
Tsumura & Co demonstrates strong financial performance with significant revenue and profit growth, robust margins, low leverage, and a solid capital base. Cash flow metrics indicate effective management, although there is room for improvement in returns on equity and cash flow efficiency.
Income Statement
85
Very Positive
Tsumura & Co has demonstrated strong revenue growth with a 20.06% increase from the previous year. The Gross Profit Margin for the latest period stands at 50.04%, indicating robust cost management. The Net Profit Margin is also healthy at 17.91%, reflecting effective control over operating expenses. The EBIT Margin and EBITDA Margin are 22.16% and 31.61%, respectively, showcasing operational efficiency. These figures signify a company that is both growing and maintaining profitability.
Balance Sheet
77
Positive
The company exhibits a stable financial structure with a Debt-to-Equity Ratio of 0.23, indicating manageable leverage. The Return on Equity is 10.79%, which is satisfactory but shows room for improvement in generating returns for shareholders. The Equity Ratio of 64.71% suggests a strong capital base, enhancing financial stability and reducing risk. Overall, the balance sheet reflects a well-capitalized company with good financial health.
Cash Flow
80
Positive
Tsumura & Co has shown substantial improvement in Free Cash Flow, achieving a positive turnaround with a Free Cash Flow Growth Rate of 143.14%. The Operating Cash Flow to Net Income Ratio is 1.04, indicating efficient cash generation relative to earnings. The Free Cash Flow to Net Income Ratio is 0.19, suggesting that although cash flow generation is improving, there is still potential for enhancement. The company demonstrates strong cash flow management, supporting its growth trajectory.
BreakdownMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income Statement
Total Revenue181.09B150.84B140.04B129.55B130.88B
Gross Profit90.58B68.82B68.28B66.47B74.93B
EBITDA57.25B34.82B31.53B31.57B28.00B
Net Income32.43B16.71B16.48B18.84B15.33B
Balance Sheet
Total Assets464.38B428.25B396.81B350.98B319.06B
Cash, Cash Equivalents and Short-Term Investments73.23B78.08B94.75B67.55B61.31B
Total Debt70.34B79.69B79.69B49.69B52.85B
Total Liabilities134.27B132.89B124.57B92.87B85.89B
Stockholders Equity300.53B270.80B252.04B239.77B217.78B
Cash Flow
Free Cash Flow6.23B-14.45B1.74B10.73B6.69B
Operating Cash Flow33.82B5.61B16.45B21.31B16.10B
Investing Cash Flow-24.97B-19.35B-15.49B-9.11B-7.35B
Financing Cash Flow-19.87B-4.42B24.42B-8.18B-10.43B

Tsumura & Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3503.00
Price Trends
50DMA
3634.24
Negative
100DMA
3950.41
Negative
200DMA
4274.49
Negative
Market Momentum
MACD
-26.72
Negative
RSI
58.09
Neutral
STOCH
88.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4540, the sentiment is Negative. The current price of 3503 is above the 20-day moving average (MA) of 3395.95, below the 50-day MA of 3634.24, and below the 200-day MA of 4274.49, indicating a neutral trend. The MACD of -26.72 indicates Negative momentum. The RSI at 58.09 is Neutral, neither overbought nor oversold. The STOCH value of 88.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4540.

Tsumura & Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
69
Neutral
$266.55B8.1611.16%3.90%20.05%94.28%
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
$2.48B17.6713.50%
$2.02B14.417.90%0.01%
$1.13B15.085.47%0.02%
$1.23B28.254.56%2.27%
71
Outperform
¥77.96B9.36
0.68%8.83%70.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4540
Tsumura & Co
3,525.00
-504.42
-12.52%
DNPUF
Sumitomo Dainippon Pharma Co
6.50
4.04
164.23%
HTSUF
Hisamitsu Pharmaceutical Co
27.68
4.98
21.94%
KSPHF
Kissei Pharmaceutical Co
27.13
7.36
37.23%
TRXPF
Torii Pharmaceutical Co
36.62
13.55
58.73%
JP:4569
KYORIN Pharmaceutical Co.,Ltd.
1,490.00
-137.93
-8.47%

Tsumura & Co Corporate Events

Tsumura Expands in China with Strategic Acquisition
Jun 18, 2025

Tsumura & Co. has announced that its subsidiary, Tsumura China Inc., will acquire a 51% stake in Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd. This strategic acquisition aims to expand Tsumura’s crude drug platform in China, leveraging Hongqiao’s sales capabilities and Tsumura’s expertise in personalized medicine and quality assurance. The move is expected to enhance product quality and increase convenience for patients, aligning with Tsumura’s vision to contribute to the health of the Chinese population.

The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.

Tsumura & Co. Completes Share Repurchase Program
Jun 11, 2025

Tsumura & Co. has concluded its share repurchase program, acquiring 530,400 shares at a total cost of 1,971,140,100 yen. This move, completed on the Tokyo Stock Exchange, marks the end of a strategic initiative resolved by the Board of Directors to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.

Tsumura & Co. Reports Progress on Share Repurchase Program
May 12, 2025

Tsumura & Co. has announced the intermediate results of its share repurchase program, which was initiated following a board resolution in February 2025. As of April 30, 2025, the company has repurchased 707,300 shares at a total cost of approximately 3.03 billion yen, reflecting its strategic efforts to enhance shareholder value and optimize capital structure.

Tsumura & Co. Unveils Ambitious Growth Plan for 2025-2027
May 12, 2025

Tsumura & Co. has announced its second Medium-Term Management Plan for fiscal years 2025 to 2027, focusing on growth strategies and investments to achieve ‘Cho-WA’ or harmony. The plan includes expanding the Kampo market, entering the traditional Chinese medicinal products business in China, and enhancing digital transformation to improve customer experience. The company aims for stable growth in domestic markets and expansion in China, with a target of JPY234 billion in sales and JPY43 billion in operating profit by 2027.

Tsumura & Co. Revises Stock Compensation System to Align with Long-term Vision
May 12, 2025

Tsumura & Co. announced a revision to its performance-based stock compensation system for directors and executive officers, aligning it with their long-term vision ‘Cho-WA’ 2031. The revision aims to strengthen the link between executive compensation and corporate value, promoting sustainable growth and enhancing corporate value over the medium to long term. The changes, which include increasing the maximum contribution and the number of shares granted, are subject to shareholder approval.

Tsumura & Co. Extends Employee Stock Delivery System to Boost Engagement
May 12, 2025

Tsumura & Co. has announced the continuation of its trust-type stock delivery system for employees, initially introduced in 2023. This system aims to align employee incentives with the company’s long-term visions, including sustainability and management goals, by offering shares or cash equivalents based on performance targets. The initiative is part of the company’s medium-term management plan, running from fiscal years 2025 to 2027, and is designed to enhance employee engagement and contribution to corporate objectives.

Tsumura & Co Reports Strong Financial Growth for FY 2025
May 12, 2025

Tsumura & Co reported a significant increase in its consolidated financial results for the fiscal year ended March 31, 2025, with net sales rising by 20.1% and operating profit doubling compared to the previous year. The company’s strong performance is reflected in its increased dividends and improved financial condition, indicating a robust market position and positive outlook for stakeholders.

Tsumura & Co. Reports Progress on Share Repurchase Program
Apr 7, 2025

Tsumura & Co. announced the intermediate results of its share repurchase program, where it acquired 206,400 shares at a cost of 908,870,200 yen. This move is part of a broader strategy approved by the board to repurchase up to 1,465,000 shares, with a maximum expenditure of 5 billion yen, aimed at enhancing shareholder value and optimizing capital structure.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 27, 2025